PharVision Advisers’s NovoCure NVCR Stock Holding History

PharVision Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,227	Closed	-$443K	–	476
2025 Q4	$443K	Buy	+34,227	New	+$439K	0.22%	78

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

PharVision Advisers's NVCR Position: Q1 2026 in Review

PharVision Advisers sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 34,227 shares — an estimated $443K sold.

PharVision Advisers first reported a position in NVCR in Q4 2025 and held it in 1 quarter. The position peaked at $443K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

PharVision Advisers reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 34,227 NovoCure shares in Q1 2026, an estimated $443K.
PharVision Advisers first reported a position in NovoCure in Q4 2025 and held it in 1 quarter.
PharVision Advisers's NovoCure position peaked at $443K in Q4 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.